References
- Linch D C, Winfield D, Goldstone A H, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of the BNLI randomised trial. Lancet 1993; 341: 1051–1054
- Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haematopoietic stem cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002; 359: 2065–2071
- Lin T S, Avalos B R, Penza S L, et al. Second autologous stem cell transplant for multiply relapsed Hodgkin's disease. Bone Marrow Transplant 2002; 29: 763–767
- Ahmed T, Lake D E, Beer M, et al. Single and double autotransplants for relapsing/refractory Hodgkin's disease: results of two consecutive trials. Bone Marrow Transplant 1997; 19: 449–454
- Ahmed T, Rashid K, Waheed F, et al. Long-term survival of patients with resistant lymphoma treated with tandem stem cell transplant. Leuk Lymphoma 2005; 46: 405–414
- Thomson K J, Peggs K S, Blundell E, Goldstone A H, Linch D C. A second autologous transplant may be efficaciouls in selected patients with Hodgkin's lymphoma relapsing after previous autograft. Leuk Lymph 2007; 48: 881–884
- Czyz J, Dziadziuszko R, Knopinska-Postuszny W, et al. Two autologous transplants in the treatment of patients with Hodgkin Lymphoma: analysis of prognostic factors and comparison with a single procedure. Leuk Lymph 2007; 48: 535–541
- Forrest D L, Hogge D E, Nevill T J, et al. High-dose therapy and autologous hematopoietic stem-cell transplantation does not increase the risk of second neoplasms for patients with Hodgkin's lymphoma: a comparison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem-cell transplantation. J Clin Oncol 2005; 23: 7994–8002